Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin

Biochemical Pharmacology

Volumn 67, Issue 3, 2004, Pages 411-419

  Rubic, Tina ^a   Trottmann, Matthias ^a   Lorenz, Reinhard L ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

ABCA1; HDL; Nicotinic acid; PPAR ; Reverse cholesterol transport; Scavenger receptors

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ABC TRANSPORTER; CD36 ANTIGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE;

ARTICLE; CHOLESTEROL TRANSPORT; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIPOGENESIS; LIPOLYSIS; LIVER CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 1242322495     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.09.014     Document Type: Article

References (44)

1. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8(6):1986;1245-1255.
2. Grundy S.M., Mok H.Y., Zech L., Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid Res. 22(1):1981;24-36.
3. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 17:1997;2020-2028.
4. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin accelerates intracellular Apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol. 19:1999;1051-1059.
5. D'Costa M.A., Ascio W., Angel A. Inhibition of rat and human adipocyte adenylate cyclase in the anti-lipolytic action of insulin, clofibrate and incotinic acid. Can. J. Biochem. 57:1979;1058-1063.
6. 2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 38(2):1989;263-274.
7. Boie Y., Sawyer N., Slipetz D.M., Metters K.M., Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. 270:1995;18910-18916.
8. 2. J. Biol. Chem. 277(12):2002;10459-10466.
9. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 83(5):1995;813-819.
10. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93(2):1998;241-252.
11. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O., Loubser O., Ouelette B.F., Fichter K., Ashbourne-Excoffon K.J., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J., Hayden M.R.et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22(4):1999;336-345.
12. Orso E., Broccardo C., Kaminski W.E., Bottcher A., Liebisch G., Drobnik W., Gotz A., Chambenoit O., Diederich W., Langmann T., Spruss T., Luciani M.F., Rothe G., Lackner K.J., Chimini G., Schmitz G. Transport of lipids from golgi to plasma membrane is defective in Tangier disease patients and ABC1-deficient mice. Nat. Genet. 24(2):2000;192-196.
13. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor. Science. 271(5248):1996;518-520.
14. Chinetti G., Gbaguidi F.G., Griglio S., Mallat Z., Antonucci M., Poulain P., Chapman J., Fruchart J.C., Tedgui A., Najib-Fruchart J., Staels B. CLA-1/SR-B1 is expressed in atheriosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 101(20):2000;2411-2417.
15. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V., Staels B. PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7(1):2001;53-58.
16. Oram J.F., Lawn R.M., Garvin M.R., Wade D.P. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J. Biol. Chem. 275:2000;34508-34511.
17. Ziegler-Heitbrock H.W., Thiel E., Futterer A., Herzog V., Wirtz A., Riethmueller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer. 41:1988;456-461.
18. Davies S.P., Reddy H., Caivano M., Cohan P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:2000;95-105.
19. Dostmann W.R., Taylor S.S., Genieser H.G., Jastorff B., Doskeland S.O., Ogreid D. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J. Biol. Chem. 265(18):1990;10484-10491.
20. Pietsch A., Erl W., Lorenz R.L. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem. Pharmacol. 52(3):1996;433-439.
21. Scheithe R., Heidenthal A.K., Danesch U., Mauthner E., Hapfelmeier G., Becker A., Pietsch A., Weber P.C., Hrboticky N. Acetylated LDL endocytosis by the human monocytic Mono Mac 6sr cells is not mediated by the macrophage type I and II scavenger receptors. Arterioscler. Thromb. Vasc. Biol. 17(6):1997;1024-1031.
22. Draude G., Lorenz R. TGF-β1 downregulates CD36 and scavenger receptor A but upregulates LOX-1 in human macrophages. Am. J. Physiol. Heart Circ. Physiol. 278(4):2000;H1042-H1048.
23. A T., Madden T.L. BLAST to sequences, a new tool for comprising protein and nucleotide sequences. FEMS Microbiol. Lett. 174(2):1999;247-250.
24. Applied Biosystems. ABI PRISM 7700 Sequence Detection System User Bulletin #2. Relative quantification of gene expression; 1997.
25. Alksnis M., Barkhem T., Stromstedt P.E., Ahola H., Kutoh E., Gustafsson J.A., Poellinger L., Nilsson S. High level expression of functional full length and truncated glucocorticoid receptor in Chinese hamster ovary cells. Demonstration of ligand-induced down-regulation of expressed receptor mRNA and protein. J. Biol. Chem. 266(16):1991;10078-10085.
26. Schulz T., Schiffl H., Scheithe R., Hrboticky N., Lorenz R. Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis. Am. J. Kidney Dis. 25(4):1995;564-571.
27. Osborne J.C. Jr. Delipidation of plasma lipoproteins. Methods Enzymol. 128:1986;213-222.
28. Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89(3):1997;331-340.
29. Calvo D., Gomez-Coronado D., Suarez Y., Lasuncion M.A., Vega M.A. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, VLDL. J. Lipid Res. 39(4):1998;777-788.
30. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106(4):2000;523-531.
31. Bortnick A., Rothblat G.H., Stoudt G., Hoppe K.L., Royer L.J., McNeish J., Francone O.L. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J. Biol. Chem. 275(37):2000;28634- 28640.
32. van Dam M.J., de Groot E., Clee S.M., Hovingh G.K., Roelants R., Brooks-Wilson A., Zwinderman A.H., Smit A.J., Smelt A.H., Groen A.K., Hayden M.R., Kastelein J.J. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet. 359(9300):2002;37-42.
33. Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G., Kaminski W.E., Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABCA1): evidence for sterol-dependent regulation in macrophages. Biochem. Biophys. Res. Commun. 257(1):1999;29-33.
34. Vaisman B.L., Lambert G., Amar M., Jayce C., Ito T., Shamburek R.D., Cain W.J., Fruchart-Najib J., Neufeld E.D., Remaley A.T., Brewer H.B. Jr., Santamarina-Fojo S. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J. Clin. Invest. 108(2):2001;303-309.
35. Groen A.K., Bloks V.W., Bandsma R.H.J., Ottenhoff R., Chimini G., Kuipers F. Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. J. Clin. Invest. 108(6):2001;843-850.
36. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science. 294:2001;1866-1870.
37. Lorenzen A., Stannek C., Burmeister A., Kalvish I., Schwabe U. G protein coupled receptor for nicotinic acid in mouse macrophages. Biochem. Pharmacol. 64:2002;245-248.
38. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9(3):2003;352-355.
39. Aktories K., Jakobs K.H., Schultz G. Nicotinic acid inhibits adipocyte adenylate cyclase in a hormone-like manner. FEBS Lett. 115(1):1980;11-14.
40. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., Ignar D.M., Murdock P.R., Steplewski K., Green A., Marshall F.H., Wilson S., Pite N.B. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278(11):2003;9869-9874.
41. Santamarina-Fojo S., Remaley A.T., Neufeld E.B., Brewer H.B. Jr. Regulation and intracellular trafficking of the ABCA1 transporter. J. Lipid Res. 42(9):2001;1339-1345.
42. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., Tontonoz P. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7(1):2001;161-171.
43. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345(22):2001;1583-1592.
44. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., Toth P.D., Favrot L.K., Kerzner B., Nash S.D., Bays H.E., Simmons P.D. Long-term safety and efficiency of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol. 89(6):2002;672-678.